Verseon Corporation 30 April 2019 Press release April 30, 2019 Verseon Corporation ("Verseon" or the "Company") Verseon presents oral drug candidate for diabetic eye disease...
Verseon Corporation 18 March 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). WITH THE PUBLICATION OF THIS...
Verseon is launching a security token offering (STO) aiming to set a new standard for the 21st century public offering to a globally connected investor base. To make its STO available to...
Verseon Corporation 15 March 2019 March 15, 2019 Verseon Corporation ("Verseon" or the "Company") Change of TIDM FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical...
Verseon Corporation 04 March 2019 March 4, 2019 Verseon Corporation ("Verseon" or the "Company") Additional Listing & Total Voting Rights Fremont, Calif.-Verseon, a...
Technology-based pharma company Verseon presented two lead candidates from its new class of precision oral anticoagulants (PROACs) at last week’s International Stroke Conference in...
Verseon Corporation 11 February 2019 February 11, 2019 Verseon Corporation ("Verseon" or the "Company") Verseon Presents PRecision Oral Anticoagulants (PROACs) with Low...
News) - Verseon Corp on Monday that it started dosing patients in the phase I clinical trial of VE-1902, the company's ...
Verseon’s precision oral anticoagulants (PROACs) could become the first anticoagulants suitable for long-term co-administration with antiplatelet agents for the prevention of stroke and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.